Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_assertion type Assertion NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_head.
- NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_assertion description "[We conclude that lenalidomide has the potential to induce sustained hematological and cytogenetic remissions in the poor prognosis MDS subgroup of del(5q31) patients with complex chromosomal anomalies and that this is likely to improve overall survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_provenance.
- NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_assertion evidence source_evidence_literature NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_provenance.
- NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_assertion SIO_000772 15891887 NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_provenance.
- NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_assertion wasDerivedFrom befree-20150227 NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_provenance.
- NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_assertion wasGeneratedBy ECO_0000203 NP781341.RA05ZjVwNAYwfiJ43z5rUDDOLyYycL2WjouNFhT3JVQTA130_provenance.